Results · Apr-Jun 2026
Vivo Bio tech Q1 FY27 results
Sales grew 14% to ₹14.3 crore from ₹12.5 crore in Apr-Jun 2025.
Operating profit fell 8% to ₹5.1 crore, an operating margin of 35.4% (down 8.5 points from a year ago).
Net profit fell 86% to ₹0.19 crore from ₹1.3 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +1%, net profit turns positive.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 14.3 | 12.5 | +14% |
| Operating profit (EBITDA) | 5.1 | 5.5 | −8% |
| Operating margin | 35.4% | 43.9% | −8.5 pts |
| Net profit | 0.2 | 1.3 | −86% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.